Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/18/2025 | $330.00 | Buy | Citigroup |
9/2/2025 | Hold → Outperform | CLSA | |
7/16/2025 | $294.00 | Sector Perform → Outperform | RBC Capital Mkts |
7/15/2025 | $294.00 | Sector Perform → Outperform | RBC Capital Mkts |
3/19/2025 | $280.00 | Overweight | Morgan Stanley |
3/19/2025 | Overweight | Morgan Stanley | |
1/16/2025 | Buy | Goldman | |
1/10/2025 | $252.00 | Neutral | Piper Sandler |
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days. About ResmedResmed (NYSE:RMD, ASX: R
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions, and elevate sleep as a global health priority. The announcement comes ahead of the World Sleep Congress, taking place September 5–10 in Singapore. Sl
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI). The study estimates that by 2050, OSA will affect nearly 77 million U.S. adults, representing a relative1 increase of nearly 35% from 2020 and impacting 46% of adults aged 30-69. The study is the first of its kind to estimate O
8-K - RESMED INC (0000943819) (Filer)
10-K - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00
CLSA upgraded ResMed from Hold to Outperform
RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr
NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, July 31, 2025, 9:30 p.m. BSTSydney, Friday, August 1, 2025, 6:30 a.m. AEST Please note, Resmed
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa